NCT01202370View on ClinicalTrials.gov

A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Solid Malignancies
Interventions
DRUG

7-t-butyldimethylsilyl-10-hydroxycamptothecin

IV Over 1 hour Days 1, 4, 8, 12 \& 15 of a 21 day cycle (7.5 mg/m\^2).

Trial Locations (1)

40536

Markey Cancer Center, University of Kentucky, Lexington

Sponsors

Collaborators (1)

Arno Therapeutics
All Listed Sponsors
collaborator

Arno Therapeutics

INDUSTRY

lead

University of Kentucky

OTHER

NCT01202370 - A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies | Biotech Hunter | Biotech Hunter